CNV1014802产品描述:CNV1014802(GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.IC50 value: Target: sodium channel blockerLike lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. CNV1014802 received orphan-drug designation from the US Food and Drug Administration in July 2013. 公司介绍:MedChemExpress(MCE)专注于各种抑制剂、激动剂、API及化合物库,总部位于美国新泽西,分别在瑞典和上海设有欧洲区子公司和亚洲区总代理,营销网点遍及全球20多个国家地区。MCE经过多年努力已成为全球生物活性小分子领域的一流供应商, 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域,PI3K、MAPK等近千个细分靶点,超过4000个活性小分子化合物现货,以及GPCR、API、离子通道等超过20种不同类型的化合物库,同时提供从毫克到千克的专业定制合成服务。 MCE 对每批产品都进行严格的LCMS和NMR检验,其产品已被全球近万名客户广泛使用并发表大量文章、专利; MCE 定期增加各领域热门抑制剂、激动剂,不断扩增已有化合物库,以满足最新的科研需求; 数千种产品在上海有充足备货,24-48小时内送达客户; 大量产品提供免费试用装;已为全球多个知名企业、院校构建各种定制型化合物库。 产品链接:www.medchemexpress.cn/cnv1014802.html ![]() |
CNV1014802研究进展
发布日期:2017-11-01 浏览次数:0
核心提示:a href=https://www.medchemexpress.com/CNV1014802.htmlCNV1014802/a产品描述:CNV1014802(GSK-1014802) is a novel small mole
行业动态
更多...
- ATN-161 (trifluoroacetat 11-06
- AZM475271研究进展 11-06
- AVN-944研究进展 11-06
- Ascomycin研究进展 11-06
- β-Lapachone研究进展 11-06
- Anidulafungin研究进展 11-06
- Amsacrine (hydrochloride 11-06
- Amsacrine研究进展 11-06
- Uramustine研究进展 11-06
- Exherin (trifluoroacetat 11-06